Liver Cancer
Liver Cancer
Advertisement
Emily MenendezHepatocellular Carcinoma | November 23, 2024
Kaplan-Meier curves showed that patients with high TBS had significantly decreased OS and increased recurrence rates.
Read More
Laura LitwinHepatocellular Carcinoma | December 3, 2024
A recent analysis reviewed patient-level data to identify the relationship between pathological response and relapse.
Emily MenendezUnresectable HCC | October 30, 2024
Repeated use of TACE can impair liver function and stimulate tumor angiogenesis.
Richard S. Finn, MDHepatocellular Carcinoma | October 29, 2024
Dr. Richard Finn provides an overview of the key studies in liver cancer from ESMO 2024.
Lorenza Rimassa, MDUnresectable HCC | October 4, 2024
HIMALAYA found tremelimumab plus durvalumab to significantly improve overall survival over sorafenib alone.
Zachary BessetteLiver Cancer | September 19, 2024
FDA approval comes after the IMscin001 trial, an open-label, multi-center, international analysis of adult patients.
Emily MenendezLiver Cancer | September 25, 2024
A study compared the outcomes of patients with HCC who underwent upfront surgical resection versus neoadjuvant immunotherapy.
Amit Mahipal, MDHepatocellular Carcinoma | September 19, 2024
Dr. Amit Mahipal discusses a recent study on atezolizumab plus bevacizumab as a first-line treatment for HCC.
Emily MenendezUnresectable HCC | August 21, 2024
Amezalpat is a PPAR⍺ antagonist that modulates immune suppressive cells and angiogenesis in the tumor microenvironment.
Zachary BessetteUnresectable HCC | August 21, 2024
The FDA's decision to accept the sBLA is based on the encouraging results of the phase 3 CheckMate-9DW study.
Dan Kaufman, MD, PhDHepatocellular Carcinoma | September 19, 2024
Dr. Dan Kaufman discusses recent research on TGF-β and how it is linked to the development of HCC.
Emily MenendezUnresectable HCC | August 8, 2024
TACE may not be an optimal treatment strategy for patients with extensive tumor bulk or impaired liver function.
Katy MarshallUnresectable HCC | August 1, 2024
The study’s primary end point was overall survival in the inverse probability of treatment weighting.
Emily MenendezHepatocellular Carcinoma | July 18, 2024
While immunotherapy paired with VEGF inhibitors are considered first-line options, they only provide modest efficacy.
Jian-Hua Luo, MD, PhDHepatocellular Carcinoma | July 17, 2024
Dr. Luo describes the performance of the two-fusion gene + α-fetal protein logistic regression model.
Jian-Hua Luo, MD, PhDHepatocellular Carcinoma | July 17, 2024
Dr. Luo explains the potential benefits of machine learning for patients with hepatocellular carcinoma. 
Katy MarshallUnresectable HCC | July 18, 2024
Median OS was 9.1 months for patients with CP-B7 and 4.7 months for those with CP-B8-C12.
Katy MarshallUnresectable HCC | July 12, 2024
The study investigated the Single Tremelimumab Regular Interval Durvalumab regimen.
Emily MenendezHepatocellular Carcinoma | June 27, 2024
While TACE is a common treatment for HCC, the procedure alone is associated with unsatisfactory survival benefits.
Katy MarshallHepatocellular Carcinoma | June 24, 2024
Dr. Luo and colleagues identified a need for increased screening measures for patients with HCC.
Advertisement
Advertisement
Advertisement
Latest News

December 13, 2024